Plain-English translation of NCT06839066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called HLX43 in patients whose nasopharyngeal cancer has come back or spread after previous treatments have failed. HLX43 works by helping your immune system recognize and fight cancer cells. The trial will compare three different doses of the medication to find the safest and most effective amount.
Nasopharyngeal cancer that returns or spreads after standard treatments is very difficult to treat, and patients need new options. This medication is being tested because early research suggests it may help patients whose cancer has stopped responding to other therapies.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (injection into your vein) once every 3 weeks. You would continue treatment as long as it is helping control your cancer and you are tolerating it well, or until your cancer progresses, you experience unacceptable side effects, or you decide to stop. You will have regular medical visits and scans to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China